ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,929.04
      2.53%
      US Tech 100
      20,197.20
      2.58%
      Dow Jones
      43,729.93
      3.57%
      Brent Oil
      75.455
      0.51%
      Bitcoin
      75,088.21
      -0.73%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Inozyme Pharma Inc (INZY)

      7. Inozyme Pharma Inc (INZY) News

      Inozyme Pharma Inc

      Inozyme Pharma Inc (INZY)

      NASDAQ
      4.23
      0.16
      (3.93%)
      Closed November 06 4:00PM
      Delayed by 15 minutes
      4.23
      0.00
      (0.00%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      INZY News

      Official News Only

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 05 2024
      INZY (3.93%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 05 2024
      INZY (3.93%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      October 24 2024
      INZY (3.93%)

      Form SC 13G - Statement of Beneficial Ownership by Certain Investors
      Edgar (US Regulatory)
      October 24 2024
      INZY (3.93%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      October 03 2024
      INZY (3.93%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      August 06 2024
      INZY (3.93%)

      Form 424B5 - Prospectus [Rule 424(b)(5)]
      Edgar (US Regulatory)
      August 06 2024
      INZY (3.93%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      August 06 2024
      INZY (3.93%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      August 06 2024
      INZY (3.93%)

      INZY Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      INZY under $6
      👍️0
      AJ Freely AJ Freely 1 year ago
      $INZY - 👆Up 7% Pre-Market/ Current Price $5.12
      Pivotal bioVenture Partners Fund I, L.P purchases
      835k shares equal to $4m investment
      👍️0
      Monksdream Monksdream 1 year ago
      INZY new 52 week high
      👍️0
      INFINITI INFINITI 2 years ago
      Loading
      👍️0
      Jess070283 Jess070283 2 years ago
      Have a feeling this about to squeeze into a halt soon…..
      👍️0
      tj9938 tj9938 2 years ago
      Great week so far. Gotta keep it movin.
      👍️0
      tj9938 tj9938 2 years ago
      Quietest board out there
      👍️0
      ErnieBilco ErnieBilco 3 years ago
      Grabbed a starter here today
      👍️0
      crudeoil24 crudeoil24 3 years ago
      INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

      (i) Deep Track Capital, LP

      (ii) Deep Track Biotechnology Master Fund, Ltd.

      (iii) David Kroin

      INZY
      👍️0
      tw0122 tw0122 3 years ago
      I like the BioXc chart looks better. Thanks for all the good insight.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      The offering is expected to close on or about April 19, 2022
      👍️0
      tw0122 tw0122 3 years ago
      This analyst know about the offering?
      Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      PT > 33.00
      👍️0
      crudeoil24 crudeoil24 3 years ago
      H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
      👍️0

      Your Recent History

      NASDAQ
      INZY
      Inozyme Pharma
      Delayed Upgrade Clock